PSMA PET/CT用于评估接受雄激素受体通路抑制剂治疗的转移性去势抵抗性前列腺癌患者的疗效反应及总生存预测
回顾性分析30例接受阿比特龙或恩扎卢胺治疗的mCRPC患者,于基线及治疗后12±4周行68Ga-PSMA-11 PET/CT,按EAU/EANM标准与RECIP 1.0标准将患者分为PSMA反应者与无反应者。中位随访25个月,两种标准下PSMA反应者的中位总生存均显著长于无反应者,两种标准预测准确性无显著差异,未观察到PSMA闪烁现象。
要点
- 按EAU/EANM标准,13例(43%)为PSMA无反应者;按RECIP 1.0标准,11例(37%)为PSMA无反应者。
- PSMA反应者中位总生存54个月,无反应者22个月,EAU/EANM标准HR 6.9(95%CI 1.9-26,P=0.004),RECIP 1.0标准HR 5.6(95%CI 1.69-18.26,P=0.005)。
- 两种标准预测准确性无显著差异(C-index 0.79 vs 0.76,P=0.54),未观察到PSMA闪烁现象。
核心结论
- PSMA PET/CT是mCRPC患者接受ARPI治疗开始后3个月时进行疗效评估和总生存预测的有价值的影像生物标志物。
- 所提出的两种PSMA反应标准(EAU/EANM与RECIP 1.0)似乎表现相当。
- 未观察到PSMA闪烁现象。
- 强烈需要对这些发现进行前瞻性验证。
研究设计与样本
- 回顾性分析30例接受ARPI(阿比特龙醋酸酯或恩扎卢胺)治疗的mCRPC患者。
- 患者在治疗开始前8周内(基线)及治疗开始后12±4周行68Ga-PSMA-11 PET/CT。
- 采用固定阈值法(SUV≥3)计算总PSMA肿瘤体积,依据EAU/EANM标准与RECIP 1.0标准将患者分为PSMA反应者(完全缓解、部分缓解或疾病稳定)与PSMA无反应者(疾病进展)。
- 基于PSA将患者分为生化反应者(PSA下降至少50%)与无反应者,采用Φ系数评估PSMA与PSA反应的相关性。
- 采用Cox回归风险模型和Kaplan-Meier法进行生存分析,并检验两种反应标准的预测准确性。
主要发现
- 按EAU/EANM标准,13例(43%)为PSMA无反应者;按RECIP 1.0标准,11例(37%)为PSMA无反应者。
- 两种标准下PSMA反应与PSA反应均呈显著相关(Φ分别为0.79和0.66)。
- 中位随访25个月(四分位距21-43个月),EAU/EANM标准下PSMA反应者中位总生存54个月 vs PSMA无反应者22个月,HR 6.9(95%CI 1.9-26,P=0.004)。
- RECIP 1.0标准下PSMA反应者中位总生存54个月 vs PSMA无反应者22个月,HR 5.6(95%CI 1.69-18.26,P=0.005)。
- 两种标准预测准确性无显著差异(C-index 0.79 vs 0.76,P=0.54),第二次PSMA PET检查未观察到闪烁现象。
关键数值与推荐
- EAU/EANM标准与RECIP 1.0标准用于PSMA反应评估:PSMA反应者包括完全缓解、部分缓解或疾病稳定,PSMA无反应者为疾病进展。
- PSA生化反应定义为PSA下降至少50%,否则为无反应者。
- 总PSMA肿瘤体积采用固定阈值法(SUV≥3)计算。
- EAU/EANM标准下PSMA反应者中位总生存54个月 vs 无反应者22个月,HR 6.9(95%CI 1.9-26,P=0.004)。
- RECIP 1.0标准下PSMA反应者中位总生存54个月 vs 无反应者22个月,HR 5.6(95%CI 1.69-18.26,P=0.005);两种标准C-index 0.79 vs 0.76(P=0.54)。
临床怎么用
- 作者认为,在mCRPC患者ARPI治疗开始后3个月时进行PSMA PET/CT,可作为疗效评估和总生存预测的有价值影像生物标志物。
- 作者指出,EAU/EANM与RECIP 1.0两种PSMA反应标准似乎表现相当。
- 作者强调,强烈需要对这些发现进行前瞻性验证。
局限性
- 原文指出强烈需要对这些发现进行前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to evaluate the role of prostate-specific membrane antigen (PSMA) PET/CT for response assessment and outcome prediction in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor pathway inhibitors (ARPIs), including abiraterone acetate or enzalutamide. Methods: We retrospectively analyzed 30 ARPI-treated mCRPC patients who underwent 68Ga-PSMA-11 PET/CT within 8 wk before (baseline) and 12 ± 4 wk after treatment initiation. Total PSMA tumor volume was calculated using the fixed threshold method (SUV ≥ 3). Patients were categorized as PSMA responders (PSMA-Rs) or PSMA nonresponders (PSMA-NRs) on the basis of both European Association of Urology/European Association of Nuclear Medicine (EAU/EANM) criteria and Response Evaluation Criteria in PSMA PET/CT (RECIP) 1.0. PSMA-R included patients with a complete response, a partial response, or stable disease, and PSMA-NR included those with progressive disease. On the basis of prostate-specific antigen (PSA), patients were classified as biochemical responders if PSA decreased by at least 50% and as nonresponders if it did not. The Φ-coefficient was used to evaluate the correlation of PSMA- and PSA-based responses. Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method. Predictive accuracy was tested for both response criteria. Results: On the basis of PSMA PET/CT, 13 (43%) patients were PSMA-NR according to the EAU/EANM criteria and 11 (37%) patients were PSMA-NR according to RECIP 1.0. Significant correlations were observed between PSMA- and PSA-based responses for both criteria (Φ = 0.79 and 0.66, respectively). After a median follow-up of 25 mo (interquartile range, 21-43 mo), the median overall survival was significantly longer for PSMA-R than PSMA-NR (54 vs. 22 mo) for both the EAU/EANM criteria and RECIP 1.0, with hazard ratios of 6.9 (95% CI, 1.9-26; P = 0.004) and 5.6 (95% CI, 1.69-18.26, P = 0.005), respectively. No significant difference in predictive accuracy was found between the 2 criteria (C-index, 0.79 vs. 0.76, respectively, P = 0.54). Flare phenomena at the second PSMA PET study were not observed in our cohort. Conclusion: Our results demonstrate that PSMA PET/CT is a valuable imaging biomarker for response assessment and overall survival prediction when performed at 3 mo after ARPI treatment initiation in mCRPC patients. Both proposed PSMA response criteria (EAU/EANM and RECIP 1.0) seem to perform equally well. No PSMA flare was observed. Prospective validation of these findings is strongly needed.
引用
- Shagera QA, Karfis I, Kristanto P, et al. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. J Nucl Med. 2023. PMID: 37770114. doi:10.2967/jnumed.123.265874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。